The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma

Radiotherapy and Oncology

Volumn 48, Issue 2, 1998, Pages 203-207

  Aref, I ^a   Eapen, L ^a   Agboola, O ^a   Cross, P ^a  

^a OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

Carcinoma; Nadir prostatic specific antigen; Prostate; Radiotherapy; Time to nadir

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CARCINOMA; SCORING SYSTEM; TREATMENT FAILURE; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADENOCARCINOMA; AGED; ANALYSIS OF VARIANCE; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; FORECASTING; HUMANS; MALE; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT FAILURE;

EID: 0031690574     PISSN: 01678140     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-8140(98)00061-9     Document Type: Article

References (20)

1. Cox, D. Regression models and life tables (with discussion). J. R. Stat. Soc. B. 34: 187-220, 1972.
2. Critz, F.A., Levinson, A.K., Williams, W.H. and Holiday, D.A. Prostate-specific antigen nadir: the optimum level after irradiation for prostate cancer. J. Clin. Oncol. 4(11): 2893-2900, 1996.
3. D'Amico, A.V. and Hanks, G.E. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 72(9): 2638-2643, 1993.
4. Frazier, H.A., Robertson, J.E., Humphrey, P.A. and Paulson, D.F. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy. J. Urol. 149: 516-518, 1993.
5. Hudson, M.A., Bahnson, R.R. and Catalona, W.J. Clinical use of prostate specific antigen in patients with prostate cancer. J. Urol. 142: 1011, 1989.
6. Kaplan, I.D., Cox, R.S. and Bagshaw, M.A. Prostate specific antigen after external beam radiotherapy for prostate cancer: follow-up. J. Urol. 149: 519-522, 1993.
7. Lange, P.H., Ercole, C.J., Lightner, D.J., et al. The value of serum prostate specific antigen determinations before and after radical prostatectomy. J. Urol. 141: 873-879, 1989.
8. Leibel, S.A., Zelefsky, M.J., Kutcher, G.J., et al. Three-dimensional conformal radiation therapy in localized carcinoma of the prostate: interim report of a phase I dose-escalation study. J. Urol. 152: 1792- 1798, 1994.
9. Lee, W.R., Hanks, G.E., Schultheiss, T.E., et al. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J. Clin. Oncol. 13: 464-469, 1995.
10. Lee, W.R., Hanlon, A.L. and Hanks, G.E. Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer: the relationship between nadir level and disease free survival. J. Urol. 156: 450-453, 1996.
11. Peto, R. and Peto, J. Asymptomatically efficient rank invariant test procedures (with discussion). J. R. Stat. Soc. A 135: 185-206, 1972.
12. Pollack, A., Zagars, G.K. and Kavadi, V.S. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer. Cancer 74(2): 670-678, 1994.
13. Ritter, M.A., Messing, E.M., Shanahan, T.G., et al. Prostate specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J. Clin. Oncol. 10: 1208-1217, 1992.
14. Russell, K.J., Dunatov, C., Hafermann, M.D., et al. Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with primary radiation therapy. J. Urol. 146: 1046-1052, 1991.
15. Schellhammer, P.F., El-Mahdi, A.M., Wright, G.L., et al. Prostate specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of the prostate. Urology 42: 13-20, 1993.
16. Willett, C.G., Zietman, A.L., Shipley, W.U. and Coen, J.J. The effect of pelvic radiation therapy on serum levels of prostate specific antigen. J. Urol. 151: 1579-1581, 1994.
17. Zagars, G.K. and von Eschenbach, A.C. Prostate-specific antigen: an important marker for prostate cancer treated by external beam radiation therapy. Cancer 72: 538-548, 1993.
18. Zeitman, A.L., Coen, J.J., Dallow, K.C. and Shipley, W.U. The treatment of prostate cancer by conventional radiation therapy: an analysis of longterm outcome. Int. J. Radiat. Oncol. Biol. Phys. 32: 287-292, 1995.
19. Zeitman, A.L., Shipley, W.U. and Coen, J.J. Radical prostatectomy and radical radiation therapy for clinical stages T1 to T2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen follow-up. J. Urol. 152: 1806-1812, 1994.
20. Consensus Statement: Guidelines for PSA Following Radiation Therapy. Int. J. Rad. Oncol. Biol. Phys. 37: 1035-1041, 1997.